Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study

Nutrition Research

Volumn 29, Issue 5, 2009, Pages 298-304

  Levy, Robert M ^a   Saikovsky, Roman ^b   Shmidt, Evgeniya ^c   Khokhlov, Alexander ^d   Burnett, Bruce P ^a  

^a PRIMUS PHARMACEUTICALS INC   (United States)

^b Federal Agency on Public Health and Social Development   (Russian Federation)

^c NATIONAL UNIVERSITY OF SCIENCE AND TECHNOLOGY MISIS   (Russian Federation)

^d The Second City Hospital   (Russian Federation)

Author keywords

Baicalin; Catechin; Clinical trial; Comparator; Cyclooxygenase; Dual inhibition; Flavocoxid; Flavonoid; Limbrel; Lipoxygenase; Medical food; Nonsteroidal anti inflammatory drugs; NSAID; Osteoarthritis; Randomized trial; VAS; WOMAC

Indexed keywords

ANTIRHEUMATIC AGENT; FLAVOCOXID; LIMBREL; NAPROXEN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMMON COLD; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FACIAL SWELLING; FEMALE; GASTROINTESTINAL DISEASE; HEARTBURN; HUMAN; HYPERTENSION; INSOMNIA; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; OCCULT BLOOD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SWELLING; SYMPTOMATOLOGY; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATECHIN; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FLAVONOIDS; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; PHYTOTHERAPY; PILOT PROJECTS; PLANT EXTRACTS; SCUTELLARIA;

EID: 67449086585     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2009.04.003     Document Type: Article

References (55)

1. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., et al. National Arthritis Data: estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58 (2008) 26-35
2. Andersen R.E., Crespo C.J., Ling S.M., Bathon J.M., and Bartlett S.J. Prevalence of significant knee pain among older Americans: results from the Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 47 (1999) 1435-1438
3. Dillon C.F., Rasch E.K., Gu Q., and Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. J Rheumatol 33 (2006) 2271-2279
4. Mili F., Helmick C.G., and Zack M.M. Prevalence of arthritis: analysis of data from the US Behavioral Risk Factor Surveillance System, 1996-99. J Rheumatol 29 (2002) 1981-1988
5. Grotle M., Hagen K.B., Natvig B., Dahl F.A., and Kvien T.K. Prevalence and burden of osteoarthritis: results from a population survey in Norway. J Rheumatol 35 (2008) 677-684
6. Sale J.E., Gignac M., and Hawker G. The relationship between disease symptoms, life events, coping and treatment, and depression among older adults with osteoarthritis. J Rheumatol 35 (2008) 335-342
7. Salaffi F., Carotti M., Stancati A., and Grassi W. Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res 17 (2005) 255-263
8. Ethgen O., Vanparijs P., Delhalle S., Rosant S., Bruyere O., and Reginster J.Y. Social support and health-related quality of life in hip and knee osteoarthritis. Qual Life Res 13 (2004) 321-330
9. Jinks C., Jordan K., and Croft P. Osteoarthritis as a public health problem: the impact of developing knee pain on physical function in adults living in the community: (KNEST 3). Rheumatology (Oxford) 46 (2007) 877-881
10. Dannhardt G., and Kiefer W. Cyclooxygenase inhibitors-current status and future prospects. Eur J Med Chem 36 (2001) 109-126
11. Kirchner T., Aparicio B., Argentieri D.C., Lau C.Y., and Ritchie D.M. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids 56 (1997) 417-423
12. Burnett B.P., Levy R., and Cole B.J. Metabolic mechanisms in the pathogenesis of osteoarthritis. A review. J Knee Surg 19 (2006) 191-197
13. Martel-Pelletier J., Mineau F., Fahmi H., Laufer S., Reboul P., Boileau C., et al. Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids. Arthritis Rheum 50 (2004) 3925-3933
14. Blower A.L., Brooks A., Fenn G.C., Hill A., Pearce M.Y., Morant S., et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 11 (1997) 283-291
15. Hawkey C.J., Cullen D.J., Greenwood D.C., Wilson J.V., and Logan R.F. Prescribing of nonsteroidal anti-inflammatory drugs in general practice: determinants and consequences. Aliment Pharmacol Ther 11 (1997) 293-298
16. Adis International Limited. Naproxcinod: AZD 3582, HCT 3012, Naproxen Nitroxybutylester, Nitronaproxen, NO-Naproxen. Drugs R D 8 (2007) 255-258
17. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 343 (2000) 1520-1528
18. Solomon D.H., Schneeweiss S., Glynn R.J., Kiyota Y., Levin R., Mogun H., et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109 (2004) 2068-2073
19. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
20. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
21. Marcouiller P., Pelletier J.P., Guévremont M., Martel-Pelletier J., Ranger P., Laufer S., et al. Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis. J Rheumatol 32 (2005) 704-712
22. Hudson N., Balsitis M., Everitt S., and Hawkey C.J. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 34 (1993) 742-747
23. Middleton Jr. E., Kandaswami C., and Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52 (2000) 673-751
24. Yoon J.H., and Baek S.J. Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J 46 (2005) 585-596
25. Bremner P., and Heinrich M. Natural products as targeted modulators of the nuclear factor-kappaB pathway. J Pharm Pharmacol 54 (2002) 453-472
26. Nam H.N. Naturally occurring NFKappaB inhibitors 2006. Med Chem 6 (2006) 945-951
27. McQuillan W.M. Conservative management of osteoarthritis of the hip. Ann Clin Res 5 (1973) 49-59
28. Adegbehingbe O.O., Adesanya S.A., Idowu T.O., Okimi O.C., Oyelami O.A., and Iwalewa E.O. Clinical effects of Garcinia kola in knee osteoarthritis. J Orthop Surg 3 (2008) 34 10.1186/1749-799X-3-34
29. Cisar P., Jany R., Waczulikova I., Sumegova K., Muchova J., Vojtassak J., et al. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytother Res 22 (2008) 1087-1092
30. Belcaro G., Cesarone M.R., Errichi S., Zulli C., Errichi B.M., Vinciguerra G., et al. Treatment of osteoarthritis with pycnogenol. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytother Res 22 (2008) 518-523
31. Farid R., Mirfeizi Z., Mirheidari M., Rezaieyazdi Z., Mansouri H., Esmaelli H., et al. Pycnogenol supplementation reduces pain and stiffness and improves physical function in adults with knee osteoarthritis. Nutr Res 27 (2007) 692-697
32. Altavilla D., Squadrito F., Bitto A., Polito F., Burnett B.P., Di Stefano V., et al. Flavocoxid, a dual Inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin stimulated macrophages. Br J Pharmacol (2009) [in press]
33. Burnett B.P., Jia Q., Zhao Y., and Levy R.M. A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food 10 (2007) 442-451
34. Burnett B.P., Silva S., Mesches M.H., and Jia Q. Safety evaluation of a combination, defined extract of Scutellaria baicalensis and Acacia catechu. J Food Biochem 31 (2007) 797-825
35. Jinks C., Jordan K., and Croft P. Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pain 100 (2002) 55-64
36. Wolfe F. Determinants of WOMAC function, pain and stiffness scores: evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia. Rheumatology (Oxford) 38 (1999) 355-361
37. Baron G., Tubach F., Ravaud P., Logeart I., and Dougados M. Validation of a short form of the Western Ontario and McMaster Universities Osteoarthritis Index function subscale in hip and knee osteoarthritis. Arthritis Rheum 57 (2007) 633-638
38. Melzack R., and Katz J. Pain measurement in persons in pain. In: Wall P., and Melzack R. (Eds). Textbook of Pain vol. 4 (1999), Churchill Livingstone, Edinburgh 129-164
39. Kellgren J.H., and Lawrence J.S. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16 (1957) 494-502
40. Ong C.K., Lirk P., Tan C.H., and Seymour R.A. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 5 (2007) 19-34
41. Martel-Pelletier J., Lajeunesse D., Reboul P., and Pelletier J.P. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 62 (2003) 501-509
42. Nakahata N., Kutsuwa M., Kyo R., Kubo M., Hayashi K., and Ohizumi Y. Analysis of inhibitory effects of scutellariae radix and baicalein on prostaglandin E2 production in rat C6 glioma cells. Am J Chin Med 26 (1998) 311-323
43. Chou T.C., Chang L.P., Li C.Y., Wong C.S., and Yang S.P. The antiinflammatory and analgesic effects of baicalin in carrageenan-evoked thermal hyperalgesia. Anesth Analg 97 (2003) 1724-1729
44. Chen Y.C., Shen S.C., Chen L.G., Lee T.J., and Yang L.L. Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide. Biochem Pharmacol 61 (2001) 1417-1427
45. Butenko I.G., Gladtchenko S.V., and Galushko S.V. Anti-inflammatory properties and inhibition of leukotriene C4 biosynthesis in vitro by flavonoid baicalein from Scutellaria baicalensis georgy roots. Agents Actions 39 Spec No (1993) C49-C51
46. Ahmed S., Rahman A., Hasnain A., Lalonde M., Goldberg V.M., and Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med 33 (2002) 1097-1105
47. Lin Y.L., and Lin J.K. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol Pharmacol 52 (1997) 465-472
48. Adcocks C., Collin P., and Buttle D.J. Catechins from green tea (Camellia sinensis) inhibit bovine and human cartilage proteoglycan and type II collagen degradation in vitro. J Nutr 132 (2002) 341-346
49. Zhang J., Stanley R.A., Adaim A., Melton L.D., and Skinner M.A. Free radical scavenging and cytoprotective activities of phenolic antioxidants. Mol Nutr Food Res 50 (2006) 996-1005
50. Nomikos T., Fragopoulou E., and Antonopoulou S. Food ingredients and lipid mediators. Curr Nutr Food Sci 3 (2007) 255-276
51. Wang S., Noh S.K., and Koo S.I. Green tea catechins inhibit pancreatic phospholipase A(2) and intestinal absorption of lipids in ovariectomized rats. J Nutr Biochem 17 (2006) 492-498
52. Zhang X.P., Tian H., Lai Y.H., Chen L., Zhang L., Cheng Q.H., et al. Protective effects and mechanisms of baicalin and octreotide on renal injury of rats with severe acute pancreatitis. World J Gastroenterol 13 (2007) 5079-5089
53. Hikiji H., Takato T., Shimizu T., and Ishii S. The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease. Prog Lipid Res 47 (2008) 107-126
54. Kowanko I.C., Bates E.J., and Ferrante A. Platelet-activating factor inhibits proteoglycan synthesis and enhances neutrophil-mediated proteoglycan degradation in cartilage explants. Arthritis Rheum 35 (1992) 918-925
55. Balestrieri M.L., Castaldo D., Balestrieri C., Quagliuolo L., Giovane A., and Servillo L. Modulation by flavonoids of PAF and related phospholipids in endothelial cells during oxidative stress. J Lipid Res 44 (2003) 380-387